Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1485-1494

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1485-1494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 9, 2015-09 ,pp. : 1055-1065

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1105-1111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation

By  

HEPATOLOGY, Vol. 31, Iss. 6, 2000-06 ,pp. : 1345-1350

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 408-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 11, 2015-11 ,pp. : 2442-2447

John Wiley & Sons Inc

Access to resources Recommend Favorite